In mouse models of NSCLC, cucurbitacin B effectively inhibits tumor growth and shows superior anti-tumor effects compared to standard treatments, underscoring its potential as a targeted therapy through the TLR4/NLRP3/GSDMD signaling axis [90]. Here, TLR4 is linked to non-small cell lung carcinoma.